Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy

International Journal of Medical Informatics

Volumn 103, Issue , 2017, Pages 32-41

  Baker, Karl ^a   Dunwoodie, Elaine ^b   Jones, Richard G ^c   Newsham, Alex ^d   Johnson, Owen ^a,d   Price, Christopher P ^e   Wolstenholme, Jane ^e   Leal, Jose ^e   McGinley, Patrick ^f   Twelves, Chris ^b   Hall, Geoff ^b  

^a Leeds Innovation Centre X Lab Ltd   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST   (United Kingdom)

Author keywords

Care pathways; Drug therapy; Electronic health records; Episode of care; Neoplasms; Process mining

Indexed keywords

COST EFFECTIVENESS; DATA MINING; DIAGNOSIS; DISEASES; DRUG THERAPY; HEALTH; HOSPITALS; ITERATIVE METHODS; MARKOV PROCESSES; QUALITY ASSURANCE; RECORDS MANAGEMENT; SEMANTICS;

CARE PATHWAYS; ELECTRONIC HEALTH RECORD; EPISODE OF CARE; NEOPLASMS; PROCESS MINING;

CHEMOTHERAPY;

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; OXALIPLATIN; PLATINUM COMPLEX;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PATHWAY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DATA MINING; ELECTRONIC HEALTH RECORD; HOME MONITORING; HUMAN; METASTATIC BREAST CANCER; NEUTROPENIA; PRIORITY JOURNAL; SOFTWARE; UNITED KINGDOM; BREAST TUMOR; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; FEMALE; MARKOV CHAIN; MEASUREMENT ACCURACY; PROCEDURES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; CRITICAL PATHWAYS; DATA ACCURACY; DATA MINING; ELECTRONIC HEALTH RECORDS; FEMALE; FLUOROURACIL; HUMANS; MARKOV CHAINS; ORGANOPLATINUM COMPOUNDS;

EID: 85017565442     PISSN: 13865056     EISSN: 18728243     Source Type: Journal    
DOI: 10.1016/j.ijmedinf.2017.03.011     Document Type: Article

References (27)

1. [1] Gray, J.M., Four box health care: development in a time of zero growth. Lancet 322:8360 (1983), 1185–1186.
2. [2] Christensen, C.M., Grossman, J.H., Hwang, J., The Innovator's Prescription. A Disruptive Solution for Health Care. 2009, McGraw-Hill, New York, 441.
3. [3] Baker, G.R., High Performing Healthcare Systems: Delivering Quality by Design. 2008, Longwoods Publishing.
4. [4] Kinsman, L., Rotter, T., James, E., Snow, P., Willis, J., What is a clinical pathway? Development of a definition to inform the debate. BMC Med., 8(1), 2010, 1.
5. [5] Rotter, T., Kinsman, L., James, E., Machotta, A., Willis, J., Snow, P., Kugler, J., The effects of clinical pathways on professional practice, patient outcomes, length of stay, and hospital costs: Cochrane systematic review and meta-analysis. Eval. Health Prof., 2011 p.0163278711407313.
6. [6] Rotter, T., Kinsman, L., James, E., Machotta, A., Steyerberg, E.W., The quality of the evidence base for clinical pathway effectiveness: room for improvement in the design of evaluation trials. BMC Med. Res. Methodol., 12(1), 2012, 1.
7. [7] Yu, P., Artz, D., Warner, J., Electronic health records (EHRs): supporting ASCO's vision of cancer care. Am. Soc. Clin. Oncol. Educ. Book, 2014, 225–231.
8. [8] Agarwal, P., Owzar, K., Next generation distributed computing for cancer research. Cancer Inform. 13:Suppl. 7 (2014), 97–109.
9. [9] Van Der Aalst, W., Process mining: discovery, conformance and enhancement of business processes. 1st ed., 2011, Springer-Verlag, Berlin/Heidelberg.
10. [10] Rojas, E., Munoz-Gama, J., Process mining in healthcare: a literature review. J. Biomed. Inform. 61 (2016), 224–236.
11. [11] Kurniati, A.P., Johnson, O., Hogg, D., Hall, G., Process mining in oncology: a literature review. 6th International Conference on Information Communication and Management (ICICM), 2016, 2016, IEEE, 291–297, 10.1109/INFOCOMAN.2016.7784260.
12. [12] Bettencourt-Silva, J.H., Clark, J., Cooper, C.S., Mills, R., Rayward-Smith, V.J., de la Iglesia, B., Building data-driven pathways from routinely collected hospital data: a case study on prostate cancer. JMIR Med. Inform., 3(3), 2015, e26.
13. [13] Caron, F., Vanthienen, J., Vanhaecht, K., Van Limbergen, E., De Weerdt, J., Baesens, B., Monitoring care processes in the gynecologic oncology department. Comput. Biol. Med. 44 (2014), 88–96.
14. [14] National Confidential Enquiry into Patient Outcome & Death (NCEPOD), For Better, for Worse? A Review of the Care of Patients Who Died Within 30 Days of Receiving Systemic Anti-cancer Therapy. 2008.
15. [15] National Chemotherapy Advisory Group (NCAG), Chemotherapy Services in England: Ensuring Quality and Safety. 2009.
16. [16] Newsham, A.C., Johnston, C., Hall, G., Leahy, M.G., Smith, A.B., Vikram, A., Donnelly, A.M., Velikova, G., Selby, P.J., Fisher, S.E., Development of an advanced database for clinical trials integrated with an electronic patient record system. Comput. Biol. Med. 41:8 (2011), 575–586.
17. [17] Johnson, O., Abiodun, S.E., Understanding what success in health information systems looks like: the Patient Pathway Management (PPM) system at Leeds. UK Acad. Inf. Syst. Conf. Proc., 2011.
18. [18] National Cancer Intelligence Network, Cancer Outcomes and Services Dataset (COSD) [Online]. 2015 Available from: http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd (accessed 14.07.16).
19. [19] Chemocare, Belfast: Clinisys. 2013.
20. [20] MOSAIQ Radiation Oncology Software. Stockholm. 2016.
21. [21] Raghupathi, W., Raghupathi, V., Big data analytics in healthcare: promise and potential. Health Inf. Sci. Syst., 2(1), 2014, 1.
22. [22] Ambler, S.W., Lines, M., Disciplined Agile Delivery. 2012, IBM Press.
23. [23] Henderson, I.C., Berry, D.A., Demetri, G.D., Cirrincione, C.T., Goldstein, L.J., Martino, S., Ingle, J.N., Cooper, M.R., Hayes, D.F., Tkaczuk, K.H., Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21:6 (2003), 976–983.
24. [24] Adams, R.A., Meade, A.M., Seymour, M.T., Wilson, R.H., Madi, A., Fisher, D., Kenny, S.L., Kay, E., Hodgkinson, E., Pope, M., Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 12:7 (2011), 642–653.
25. [25] Caldicott, F., Review of Data Security, Consent and Opt-outs. 2016.
26. [26] Dale, D.C., McCarter, G.C., Crawford, J., Lyman, G.H., Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J. Natl. Compr. Canc. Netw. 1:3 (2003), 440–454.
27. [27] Dinan, M.A., Hirsch, B.R., Lyman, G.H., Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J. Natl. Compr. Canc. Netw. 13:1 (2015), e1–e7.